--- title: "GLAUKOS (GKOS) stock listing, news and investor profile" url: "https://aibio.space/companies/glaukos/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GLAUKOS Corp (NYSE: GKOS), United States. Listing facts, related biotech companies and news on aibio.space." --- GKOS GLAUKOS Corp NYSE · United States # GLAUKOS (GKOS) news Financings · 2026-08-06 ## [SpyGlass ends June with $234.2 million and says cash lasts through 2028](https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/) Second-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that. ## Latest GLAUKOS news 1. 2026-05-22 Legal [SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027](https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/) Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027. ## GLAUKOS at a glance - **Ticker**: GKOS - **Listing**: NYSE - **Country**: United States - **Cash, Sep 30, 2026**: $162.3 million ### Related companies - [Cannabis Bioscience International Holdings](https://aibio.space/companies/cannabis-bioscience-international/) OTC: CBIH - [PULSE BIOSCIENCES, INC.](https://aibio.space/companies/pulse-biosciences/) NASDAQ: PLSE - [China Foods Holdings](https://aibio.space/companies/china-foods/) OTC: CFOO - [NEXGEL, INC.](https://aibio.space/companies/nexgel/) NASDAQ: NXGL - [ENCISION INC](https://aibio.space/companies/encision/) OTC: ECIA - [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) NASDAQ: MXCT - [Nuo Therapeutics](https://aibio.space/companies/nuo-therapeutics/) OTC: AURX - [VivoSim Labs, INC.](https://aibio.space/companies/vivosim-labs/) NASDAQ: VIVS ### Also on NYSE - [SHOULDER INNOVATIONS, INC.](https://aibio.space/companies/shoulder-innovations/) SI - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) ANRO - [Edwards Lifesciences](https://aibio.space/companies/edwards-lifesciences/) EW - [Xtant Medical Holdings](https://aibio.space/companies/xtant-medical/) XTNT - [VOLITIONRX LTD](https://aibio.space/companies/volitionrx/) VNRX - [Elanco Animal Health](https://aibio.space/companies/elanco-animal-health/) ELAN ## GLAUKOS annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$507.4 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | [$383.5 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | | Net income (loss) | [-$187.7 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | [-$146.4 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | | Cash from operations | [-$14.8 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | [-$61.3 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | | Cash and equivalents | [$90.8 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526436400/) | [$169.6 million](https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $162.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about GLAUKOS What is the ticker symbol of GLAUKOS? GLAUKOS Corp trades under the ticker GKOS on NYSE. Where is GLAUKOS listed? GLAUKOS Corp is listed on NYSE. Which country or territory is GLAUKOS listed under? Our directory records GLAUKOS Corp under United States. Does aibio.space cover GLAUKOS? aibio.space lists GLAUKOS Corp among 2,820 public biotech companies and publishes its news here as stories appear. What was GLAUKOS's revenue last year? $507.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is GLAUKOS profitable? GLAUKOS Corp reported a net loss of $187.7 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC. How much cash does GLAUKOS have? $162.3 million in cash at Sep 30, 2026, per its 10-Q. Which other companies' news mentions GLAUKOS? GLAUKOS is named in 2 of our stories about other companies, most recently: "SpyGlass ends June with $234.2 million and says cash lasts through 2028" (Aug 6, 2026); "SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027" (May 22, 2026). [Source](https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/). How can I follow GLAUKOS (GKOS) news? Press Follow on this page to add GLAUKOS to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming GLAUKOS so far, in Financings, Legal. ## Investor discussion: GLAUKOS Members talk about GLAUKOS (GKOS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:GKOS on TradingView](https://www.tradingview.com/symbols/NYSE-GKOS/). ## Listing details GLAUKOS Corp is a public biotech or pharmaceutical company listed on NYSE under the ticker GKOS, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: GLAUKOS Corp - **Ticker**: GKOS - **Listing**: NYSE - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/glaukos/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "GLAUKOS (GKOS) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/glaukos/